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DOI 10.1016/j.chembiol.2009.06.004Drugs were traditionally derived from
natural molecules. Over half of the new
drugs approved in the past 20 years can
trace their structural origins to sources as
disparate as poisonous sea snails, soil
fungus, and tree bark. In recent years,
pharmaceutical companies turned their
backs on natural products because of the
difficulty of rapidly isolating and synthe-
sizing molecules from natural sources on
a large scale. However, a number of drugs
and drug intermediates including artemisi-
nin, capsaicin, arachidonate, and amyrin
can be made using genetic techniques
coupled to chemistry.
According to David Newman, D.Phil.,
Chief, Natural Products Branch, National
Cancer Institute (NCI), the advent of
genomic techniques in the late 1970s
changed thescaleofdrugdiscovery.Phar-
maceutical companies invested heavily in
combinatorial chemistry libraries and high
throughput screening. ‘‘Companies were
looking for billion dollar drugs,’’ said New-
man. ‘‘Natural products just didn’t hack it
at the time due to time constraints.’’ While
combinatorial chemistry excels in opti-
mizing structures, only one drug, Nexvar,
resulted de novo from this method. New
compounds that mimicked natural prod-
ucts were developed through alternate
methods, such as diversity oriented syn-
thesis. According to Newman, only one
pharma in the US retains a natural prod-
ucts division, although the US arm of
a Japanese company uses natural prod-
ucts as structure leads. Smaller biotechs
are retrenching on new research once
initial compounds enter clinical trials, as
costs are substantial and VCs want fast
return on investment.
Meanwhile, research is uncovering
cryptic clusters of genes and genetic
switches that constitute more detailed
blueprints for metabolic natural product
synthesis. ‘‘Over the last five years, it
has been obvious that microbes actually
have in their genomes incredibly more
compounds than have ever been seen,’’
said Newman.
Reality Show in a Dish
A niche player, Swiss company Evolva
(http://www.evolva.com) is using an
intriguing genetic chemistry strategy to
discover novel small molecule drugs as
well as to produce difficult-to-synthesize
compounds from natural sources. Inside
Evolva’s main laboratory in Basel, an
international team of scientists subjects
yeast cells to an evolutionary sweep-
stakes based on survival. The researchers
start with a desired set of targets and use
S. cerevisiae as a work-horse organism.
They synthesize artificial chromosomes
from interesting genes isolated from
a variety of organisms. ‘‘Usually we take
a biochemical pathway of yeast optimized
for a molecule and then cross it with
a cDNA library, a collection of expressed
coding regions of a genome,’’ said Stan
Goldman, Ph.D, Director of Technology
at Evolva subsidiary Genetic Chemistry.
Evolva scientists thenmix the genes and
ligate them, constructing artificial chromo-
somes from the concatemerized genes.
The chromosomes are combined to make
new biosynthetic pathways. The scientists
insert the artificial chromosomes into the
haploid yeast as a first step in making the
library and then breed the yeast together
to make a complete library. The yeast has
to produce or optimize the desired
compound to survive. If the yeast cells
die, the molecule is booted off the island,
so to speak. The winning molecules then
goon to thenext iteration.Evolva scientists
can build a protein-protein assay into the
yeast. They can also incubate yeast in the
presence of bacteria, mammalian cells,
Instead of doing the synthesis in a test tube, the yeast cell synthe-
sizes the molecule.Chemistry & Biology 16, June 26, 2009and get assays for secretion and activity
in another complex system.
According to Goldman, it is possible to
miss certain molecules in classic dis-
covery efforts if they exist in a cell in a
concentration undetectable by conven-
tional analytic techniques, have a short
lifetime, or only appear at some specific
point in an organism’s lifecycle. ‘‘If you
take a set of genes that express a mole-
cule and put in a heterologous host, you
can have more control,’’ said Goldman.
Since Evolva randomly combines genes,
it can get everything the genes produce,
not just the end product. Instead of doing
the synthesis in a test tube, the yeast cell
synthesizes the molecule.
According to Pascal Longchamp, Ph.D,
Vice President, Business Development at
Evolva, pharmacompaniesareparticularly
interested in diverse scaffolds. ‘‘The
Evolva platform mixes genes in novel
ways, combining, for example, genes
from sponges and the human brain,’’
Longchamp said. Evolva’s patent applica-
tions cover a veritable Noah’s ark of
expressible nucleotide sequences ranging
from humans to crocodiles and butterflies,
witharchaeobacteria andcoffee thrown in.
Evolva uses concepts equivalent to the
directed-evolution technologies used for
research. These techniques are also used
by a number of companies such as Maxy-
gen (http://www.maxygen.com), which
develops protein drugs, and its spinoff Co-
dexis (http://www.codexis.com), which
developsbiocatalysts tooptimizeenzymes
to produce antibiotics, plastics, deter-
gents, and biofuels. However, Evolva
uses varied gene sequences to produce
multiple small-molecule backbones and
evolve them.
Doing What Others Couldn’t
Evolva’s commercial compounds are
a broad-spectrum antifungal compound
that is expected to enter the clinic at the
end of the year and an oral thromboxane
receptor and thromboxane synthase inhib-
itor for proteinuric kidney disease and
prevention of platelet aggregation (aimedª2009 Elsevier Ltd All rights reserved 577
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diseasepatientswhodon’t respond toPla-
vix or aspirin),which isnow inphase I.Evol-
va’s broad-spectrum antifungal (MIC-90
versus Candida 1ng/ml) has a novel
mechanism of action and overcomes
resistant fungal strains. The thromboxane
compound is potent (IC50 0.8 nM), fast
acting, and reversible, thus improving its
safety profile.
Evolva was spun out of US company
Phytera in 2004. In addition to Genetic
Chemistry in Palo Alto, Evolva also has
divisions in India and Denmark. The 70
person company was funded with USD
$34 million by seven venture capital
companies. The company mainly pays
its R&D costs through approximately $80
million in US biodefense contracts.
‘‘The most impressive part was they
had developed a new approach to do
what other companies had tried to do,
which is to use metabolic pathways from
various types of cells from invertebrate
plants, vertebrates, to develop new
compounds based on scaffolds thought
to be promising in drug development by
using the etymology of these pathways
to link together these genes,’’ said scien-
tific advisor Dr. Richard Ulevitch, whowas
involved in initial diligence for Aravis
Ventures, an investor. ‘‘They were able
to express these genes in yeast. In some
cases, the yeast itself would be part of
the high throughput screening for the
compound because they could also put
a biological readout or signal into the
yeast. A company like Kosan [Biosci-
ences] tried to do this with polyketides
and had some degree of success. It is
just another approach, different from
combinatorial chemistry that provides
you with a high throughput mechanism
to screen for leads by using derived struc-
tures that could be produced by other
methods.’’
It’s Harder to Make a Five-Legged
Dog
Willem (Pim) Stemmer, Ph.D, a scientific
advisor toEvolva,wasthe technical founder
ofMaxygen. Stemmer is nowCEO of Amu-
nix (http://www.amunix.com),whichmakes
nonimmunogenic proteins with an im-
proved half-life.
According to Stemmer, many natural
sources contain molecules that can’t be
made via chemical libraries. For example,578 Chemistry & Biology 16, June 26, 2009the NCI found a number of compounds in
sponges and other rare organisms that
were active against cancer, but it was
unable to manufacture them. ‘‘Evolva’s
approach doesn’t suffer from that because
manufacturability and activity are linked in
its process,’’ said Stemmer. ‘‘Quality and
quantity of the drug coevolve.’’
According to Stemmer, Kosan Biosci-
ences initially focused on creating a
plethora of complex polyketides but in
the end had to give up, largely because
the host organism, Streptomyces, grows
slowly and is much more difficult to work
with than yeast.
‘‘The closer you stick to natural path-
ways, the higher the quality of the result,’’
said Stemmer. ‘‘The shuffling of existing
chemical pathways is an efficient way to
recreate the chemical diversity of the
past. The chemical diversity that existed
over the past billion years can be recre-
ated simply by repeated recombination
of the existing pathways.’’ According to
Stemmer, it is more efficient to recap-
ture evolutionary history, for example, to
modify the size or coat color of a dog,
than to do something completely novel,
like making a dog with five legs. ‘‘The
remarkable thing about breeding is that
it is very conservative; you can create diver-
sity by juggling millions of mutations,
withoutpayinga functionalprice,’’observed
Stemmer.Hecautions thatwhile gene shuf-
fling techniques are ‘‘very powerful,’’ they
can be dangerous if willfully abused.
In the Meantime, Breeding
in the Black
Evolva is working on a USD $28 million
DTRA contract with Functional Genetics
(http://www.functional-genetics.com), a
Maryland-based company that develops
broad spectrum antivirals for civilian and
biodefense applications. Evolva is devel-
oping molecules for an Ebola therapeutic,
but the targets may also be relevant for
HIV and influenza. This involves an inhib-
itor for TSG101, a human protein that is
common to many viral pathways and
ubiquitous in a variety of cells. When a
cell is infected with Ebola or HIV, the
viruses ‘‘hijack’’ TSG101, reprogramming
it to the cell surface where TSG101 plays
a critical role in virus budding, allowing
the virus to escape from the cell.
‘‘Evolva came to our attention for an
interesting capability in gene shuffling,’’ª2009 Elsevier Ltd All rights reservedsaidMichael Goldblatt, CEO of Functional
Genetics. ‘‘We have, as a result, with
Evolva, come up with two strong leads
and are developing more.’’ According to
Goldblatt, one of the leads gives animals
100% protection from Ebola infection,
the other substantially lower. ‘‘We are in
the process of doing pharmacophores
around the chemistry of thesemolecules,’’
said Goldblatt. ‘‘They model well in dis-
rupting protein-protein interactions.’’ Ac-
cording to Goldblatt, Evolva’s ability to
do gene shuffling and determine in one
step in vivo what targets are toxic to cells
produced fewer false leads.
Evolva also has two preclinical com-
pounds in a USD $26.8 million DTRA
program developing immunomodulators
for infectious disease and pandemics.
According to Neil Goldsmith, Evolva
CEO, one of its preclinical compounds,
EV-009-1440, provides 50% protection
against lethal bacterial infections (in
mice), while another is comparable to
Tamiflu in its activity against influenza
and potentially synergistic in its effects
with Tamiflu.
Evolva subsidiary Genetic Chemistry
has a third USD $22.8 million contract
from the ARO to develop antibacterials
for Gram-negative bacteria. ‘‘They have
a unique ability to mix genetic pathways
across species,’’ said Dr. Jennifer
J. Becker, Ph.D., Chemical Sciences Divi-
sion, US Army Research Office. ‘‘It could
potentially lead to a wider variety of
targets. It could lead to small molecules
that may not be possible using traditional
synthetic chemistry techniques.’’
Military scientists say little about
ongoing biodefense projects, and so far
Evolva is closemouthed about its IP,
publishing few details. ‘‘It is interesting,
and I’m pro anything that can produce
novel or previously undetected natural
products,’’ said David Newman. But can
Evolva convince big pharma to go back
to natural products on a large scale?
Only if the company can prove it can
develop its novel small molecules cost
effectively. Newman feels that European
and perhaps Japanese big pharmas
could be swayed, but probably not phar-
mas in the current US business climate.
‘‘Wyeth is the only big pharma group
left,’’ Newman said.
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